GlassScriptPhysician profile
Ali Khusseyn
NPI 1396792594
$10,179.19
in general payments reported to CMS, 2019-2025
36 companies · $2,112 in 2025
The $2,112 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,747 · 2020: $1,176 · 2021: $1,731 · 2022: $1,233 · 2023: $794 · 2024: $1,386 · 2025: $2,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,647.20 | 2019-2025 | |
| Amgen INC. | $821.94 | 2019-2025 | Repatha |
| Otsuka America Pharmaceutical, INC. | $720.98 | 2023-2025 | Rexulti, Nuedexta |
| Novo Nordisk INC | $653.17 | 2019-2023 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $576.14 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $574.34 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.63 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $440.80 | 2019-2025 | Lokelma, Farxiga |
| Axsome Therapeutics, INC. | $360.98 | 2023-2025 | Auvelity, Symbravo |
| Eisai INC. | $346.24 | 2025 | |
| Novartis Pharmaceuticals Corporation | $332.30 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $322.83 | 2021-2023 | |
| Allergan, INC. | $317.77 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $304.78 | 2023-2025 | Horizant, Horizant, Edarbi |
| Ardelyx, INC. | $217.90 | 2024-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $217.38 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $205.41 | 2019-2023 | Eliquis |
| Neurocrine Biosciences, INC. | $157.89 | 2024-2025 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $130.99 | 2019 | |
| Arbor Pharmaceuticals, INC. | $130.31 | 2020-2022 | |
| Dexcom, INC. | $125.00 | 2021 | |
| Vivus LLC | $110.25 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $107.91 | 2019-2021 | |
| Lundbeck LLC | $106.95 | 2025 | Rexulti, Vyepti |
| Pfizer INC. | $97.19 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $94.51 | 2024-2025 | Zenpep |
| Acadia Pharmaceuticals INC | $81.50 | 2024-2025 | Nuplazid |
| Neurelis, INC. | $80.51 | 2025 | Valtoco |
| Shield Therapeutics INC | $72.69 | 2023-2024 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $46.45 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $44.76 | 2025 | Crexont |
| Ironwood Pharmaceuticals, INC | $24.60 | 2022 | |
| Gilead Sciences, INC. | $23.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.39 | 2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $20.99 | 2025 | Ponvory |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Khusseyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.